|Articles|December 2, 2013
Lilly Strategy: Timely, Valued Medicines to Patients
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline
Advertisement
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.
For more videos tune in to:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
2
AI and Human Collaboration Essential for Bio/pharma Innovation
3
Sustainability and Stability in Excipients
4
Centralizing AI Strategy, Ensuring Process Integrity, and Balancing Quick Wins with Long-Term Drug Design in Bio/pharma
5
